An interventional study of Exercise in Thalassemia, sponsored by University of California, San Francisco. Active, not recruiting at 2 sites in United States. Open to participants aged 14 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Thalassemia with a site in United States — 9 open to participants now, 20 under way, 8 of them phase 3. Thalassemia · United States.
Among the 104 studies in Thalassemia with a site in United States, this one is the 48th largest by planned enrollment of the 81 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, reaches primary completion later than 6 of the 19 other live ones, and was the 102nd registered.
252 studies on the registry are indexed under Thalassemia; 45 are open to participants now.
Browse Thalassemia studies →9 of the 104 studies in Thalassemia with a site in United States are open now. Recruiting first, the newest first:
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Novo Nordisk A/S · Sites in United States, Canada, Egypt and 14 more countries
Ages 2+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 2–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Thalassemia studies recruiting now, 8 (28%) set no upper age limit and 18 (62%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.
This study: 14 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 44 · Phase 3 13 · Phase 4 2
First in 1985; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 33 across 171 interventional studies indexed under Thalassemia.
Median enrollment 24 across the 81 interventional studies, 125 across the 20 observational. Of the 78 that completed or were terminated, 33 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 104 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 6 studies filed under Thalassemia — fewer than ten, so there is no comparison to draw.
7 of the studies in Thalassemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT07064941University of California, San FranciscoEffect of Exercise on Body Composition and Bone Health in Patients With Thalassemia | 2026-12-30 |
| NCT03249831City of Hope Medical CenterA Blood Stem Cell Transplant for Sickle Cell Disease | 2027-01-25 |
| NCT05736419Memorial Sloan Kettering Cancer CenterA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | 2027-02-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 104 studies in Thalassemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine if a weight bearing exercise intervention can improve body composition and bone health in adolescents and adults with Thalassemia.
The main questions it aims to answer are:
Researchers will compare participants' change in body composition, muscle mass, and muscle function during a "Usual Activity" period (12 weeks) with an exercise intervention (Period 1: 12 weeks) to see if exercise can improve body composition and muscle function.
The intervention will then be extended an additional 24 weeks for a total of 36 weeks of exercise (Period 2) to explore the change in bone mineral density between between "Usual Activity" and "Exercise Intervention" (Period 2) in individuals with Thalassemia.
During the intervention period, participants will engage in a self-directed exercise regime of either weight bearing aerobic exercise or strength training exercises (30 min/day; 5x/week).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects will participate in usual daily activities during this period
Behavioral: Exercise
Exercise for 30 min a day 5x a week with a choice between Aerobic or strength training. Subjects will choose an aerobic activity to perform 3x/week (e.g. brisk walking, hiking, jogging). They will start at 15-20 min/day depending on fitness level and build up by 5 min intervals/week as tolerated to 50 min/day or 150 min/week by 12 weeks. Subjects will choose strength exercises to perform 2x/week, on days separate from aerobic activity. They will start with 1-2 exercises (e.g. squats, lunges, planks with and without resistance) and gradually add exercises to include all muscle groups (arms, legs, chest, back, abdomen). Start with 2 sets of 10 reps, and work up to 3 sets of 15 reps of given exercises.
Total Body Lean Mass (grams)
Total body lean mass assessed by Dual Energy X-Ray Absorptiometry (DXA)
Time frame: 12 weeks (Period 1) and 36 weeks (Period 2)
Percentage Body Fat
Percentage body fat assessed by Dual Energy X-Ray Absorptiometry (DXA)
Time frame: 12 weeks (Period 1) and 36 weeks (Period 2)
6 minute walk test (6MWT)
Distanced walked during a 6MWT
Time frame: 12 weeks (Period 1) and 36 weeks (Period 2)
Vertical Jump
Vertical jump from a standing height (cm)
Time frame: 12 weeks (Period 1) and 36 weeks (Period 2)
Bone Mineral Density (BMD)
Bone mineral density at the spine, left hip, left distal radius and whole body as assessed by Dual Energy X-Ray Absorptiometry (DXA)
Time frame: 36 weeks (Period 2)
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 18 interventional studies with no phase under Thalassemia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 87. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →